Determination of Effective Half-life of I in Thyroid Cancer Patients Using Remote Dose-rate Meter

Overview

Journal EJNMMI Phys

Specialty Radiology

Date 2024 Nov 28

PMID 39609328

Authors

Laura Kaaria

Maria Lapela

Marko Seppanen

Mikael Hogerman

Johanna Ruohola

Annika Algars

Tommi Noponen

Affiliations

Soon will be listed here.

Abstract

Background: Continuously monitored external dose-rate signals from remote dose-rate meters (DRMs) were analyzed to determine the effective half-life (T) of I in differentiated thyroid cancer (DTC) patients. The aim is to gain novel understanding of the excretion of radioactive iodine (RAI) in DTC patients and to demonstrate that a remote DRM system can be reliably used for real-time monitoring of external dose-rates of DTC patients.

Methods: 110 DTC patients who received postoperative RAI therapy between September 2018 and February 2023 in Turku University Hospital were studied retrospectively. The external dose-rates of the patients were continuously monitored during their hospitalization with a remote DRM fixed in the ceiling of the isolation room. Generalized linear mixed model (GLMM) was used to analyse the association between logarithmical T and patient characteristics.

Results: The median T for all patients was 12.60 h (Q1: 10.35; Q3: 14.75 h). Longer Ts were associated with higher BMI (p = 0.004), lower GFR (p < 0.001), and diabetes (p = 0.007). Our study also revealed that neither age nor subsequent RAI therapies have a significant impact on the whole body T (p = 0.522 and p = 0.414, respectively).

Conclusion: Patients with higher BMI, decreased GFR, or diabetes have a longer whole-body T of I. Ceiling-mounted remote DMRs can reliably be used to determine patient's T. Since T values vary among patients, ceiling-mounted meters can be used to optimize the length of radiation isolation period at the hospital while improving patient comfort and staff efficiency.

References

Xu M, Feng R, Feng R, Yin X, Zhang L, Wang C . Glomerular filtration rate in patients with type 2 diabetes mellitus: is serum isthmin-1 level a possible link?. BMJ Open Diabetes Res Care. 2023; 11(4). PMC: 10462937. DOI: 10.1136/bmjdrc-2023-003402. View

Mueller-Peltzer K, von Kruchten R, Lorbeer R, Rospleszcz S, Schulz H, Peters A . Adipose tissue is associated with kidney function parameters. Sci Rep. 2023; 13(1):9151. PMC: 10244418. DOI: 10.1038/s41598-023-36390-z. View

Remy H, Borget I, Leboulleux S, Guilabert N, Lavielle F, Garsi J . 131I effective half-life and dosimetry in thyroid cancer patients. J Nucl Med. 2008; 49(9):1445-50. DOI: 10.2967/jnumed.108.052464. View

Tenhunen M, Lehtonen S, Heikkonen J, Halonen P, Maenpaa H . First-day iodine kinetics is useful for individualizing radiation safety precautions for thyroid carcinoma patients. Nucl Med Commun. 2013; 34(12):1208-15. PMC: 3815145. DOI: 10.1097/01.mnm.0000434308.87736.a5. View

Sisson J, Avram A, Lawson S, Gauger P, Doherty G . The so-called stunning of thyroid tissue. J Nucl Med. 2006; 47(9):1406-12. View

Klain M, Nappi C, De Risi M, Piscopo L, Volpe F, Manganelli M . Whole-Body Radioiodine Effective Half-Life in Patients with Differentiated Thyroid Cancer. Diagnostics (Basel). 2021; 11(10). PMC: 8535104. DOI: 10.3390/diagnostics11101740. View

Pizzato M, Li M, Vignat J, Laversanne M, Singh D, La Vecchia C . The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020. Lancet Diabetes Endocrinol. 2022; 10(4):264-272. DOI: 10.1016/S2213-8587(22)00035-3. View

Barrington S, Kettle A, ODoherty M, Wells C, Somer E, Coakley A . Radiation dose rates from patients receiving iodine-131 therapy for carcinoma of the thyroid. Eur J Nucl Med. 1996; 23(2):123-30. DOI: 10.1007/BF01731834. View

Bacher R, Hohberg M, Dietlein M, Wild M, Kobe C, Drzezga A . Thyroid Uptake and Effective Half-Life of Radioiodine in Thyroid Cancer Patients at Radioiodine Therapy and Follow-Up Whole-Body Scintigraphy Either in Hypothyroidism or Under rhTSH. J Nucl Med. 2018; 60(5):631-637. DOI: 10.2967/jnumed.118.217638. View

10.

Kumar P, Bal C, Damle N, Ballal S, Dwivedi S, Agarwala S . Lesion-Wise Comparison of Pre-Therapy and Post-Therapy Effective Half-Life of Iodine-131 in Pediatric and Young Adult Patients with Differentiated Thyroid Cancer Undergoing Radioiodine Therapy. Nucl Med Mol Imaging. 2019; 53(3):199-207. PMC: 6554380. DOI: 10.1007/s13139-019-00592-z. View

11.

Minguez P, Rodeno E, Genolla J, Dominguez M, Exposito A, Sjogreen Gleisner K . Analysis of activity uptake, effective half-life and time-integrated activity for low- and high-risk papillary thyroid cancer patients treated with 1.11 GBq and 3.7 GBq of I-NaI respectively. Phys Med. 2019; 65:143-149. DOI: 10.1016/j.ejmp.2019.08.017. View

12.

Grenfell S, Roos D, Rijken J, Higgs B, Kirkwood I . Comparison of effective I-131 half-life between thyroid hormone withdrawal and recombinant human thyroid-stimulating hormone for thyroid cancer: a retrospective study. J Med Imaging Radiat Oncol. 2014; 59(2):248-54. DOI: 10.1111/1754-9485.12238. View

13.

Sisson J, Freitas J, McDougall I, Dauer L, Hurley J, Brierley J . Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I : practice recommendations of the American Thyroid Association. Thyroid. 2011; 21(4):335-46. DOI: 10.1089/thy.2010.0403. View

14.

Willegaignon J, Malvestiti L, Guimaraes M, Sapienza M, Endo I, Neto G . 131I effective half-life (Teff) for patients with thyroid cancer. Health Phys. 2006; 91(2):119-22. DOI: 10.1097/01.HP.0000202232.98823.87. View

15.

Okkalides D . The Result of Multiple I-131 Treatments on the Effective Half-Life of Retained Radioactivity in Patients Ablated for Differentiated Thyroid Cancer: Possible Evidence for Thyroid Remnant Function Impairment. Cancer Biother Radiopharm. 2016; 31(2):58-64. DOI: 10.1089/cbr.2015.1959. View

16.

Han S, Jin S, Yoo S, Lee H, Lee S, Jeon M . A practical individualized radiation precaution based on the dose rate at release time after inpatient 131I ablation therapy. PLoS One. 2021; 16(5):e0251627. PMC: 8139448. DOI: 10.1371/journal.pone.0251627. View

17.

Hilditch T, Dempsey M, Bolster A, McMenemin R, Reed N . Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I. Eur J Nucl Med Mol Imaging. 2002; 29(6):783-8. DOI: 10.1007/s00259-002-0785-6. View

18.

Freesmeyer M, Guhne F, Kuhnel C, Opfermann T, Winkens T, Werner A . Determination of effective half-life of I in patients with differentiated thyroid carcinoma: comparison of cystatin C and creatinine-based estimation of renal function. Endocrine. 2018; 63(3):554-562. DOI: 10.1007/s12020-018-1800-4. View

19.

Wadsley J, Armstrong N, Bassett-Smith V, Beasley M, Chandler R, Cluny L . Patient Preparation and Radiation Protection Guidance for Adult Patients Undergoing Radioiodine Treatment for Thyroid Cancer in the UK. Clin Oncol (R Coll Radiol). 2022; 35(1):42-56. DOI: 10.1016/j.clon.2022.07.002. View

20.

Van Nostrand D . The benefits and risks of I-131 therapy in patients with well-differentiated thyroid cancer. Thyroid. 2009; 19(12):1381-91. DOI: 10.1089/thy.2009.1611. View